Novo Cure LTD NVCR
We take great care to ensure that the data presented and summarized in this overview for NovoCure Ltd is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NVCR
View all-
Black Rock Inc. New York, NY12.1MShares$374 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$365 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA7.92MShares$244 Million0.02% of portfolio
-
Capital World Investors Los Angeles, CA4.31MShares$133 Million0.01% of portfolio
-
Nordwand Advisors, LLC Radnor, PA3.03MShares$93.3 Million12.67% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.81MShares$86.4 Million0.03% of portfolio
-
State Street Corp Boston, MA2.73MShares$84.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.41MShares$74.1 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.32MShares$71.5 Million0.0% of portfolio
-
Baillie Gifford & CO1.66MShares$51.1 Million0.02% of portfolio
Latest Institutional Activity in NVCR
Top Purchases
Top Sells
About NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Insider Transactions at NVCR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 04
2024
|
Mukund Paravasthu Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,138
+47.29%
|
-
|
|
Nov 02
2024
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
44
-1.26%
|
$704
$16.69 P/Share
|
|
Nov 01
2024
|
Mukund Paravasthu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
160
-4.37%
|
$2,400
$15.88 P/Share
|
|
Nov 01
2024
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
598
-0.37%
|
$8,970
$15.94 P/Share
|
|
Oct 31
2024
|
Michal Nath Puri Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
810
-0.73%
|
$12,150
$15.79 P/Share
|
|
Aug 02
2024
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
688
-0.31%
|
$13,760
$20.14 P/Share
|
|
Jun 28
2024
|
Asaf Danziger Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,239
+7.52%
|
$14,868
$12.24 P/Share
|
|
Jun 28
2024
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,055
+0.42%
|
$12,660
$12.24 P/Share
|
|
Jun 28
2024
|
Barak Ben Arye General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
930
+0.78%
|
$11,160
$12.24 P/Share
|
|
Jun 28
2024
|
Michal Nath Puri Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,736
+1.54%
|
$20,832
$12.24 P/Share
|
|
Jun 28
2024
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
1,736
+1.06%
|
$20,832
$12.24 P/Share
|
|
Jun 28
2024
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,286
+0.58%
|
$15,432
$12.24 P/Share
|
|
Jun 05
2024
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
124,373
+50.0%
|
$2,736,206
$22.82 P/Share
|
|
Jun 05
2024
|
Allyson J Ocean |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+50.0%
|
-
|
|
Jun 05
2024
|
Martin J. Madden |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+17.08%
|
-
|
|
Jun 05
2024
|
David Hung |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+23.5%
|
-
|
|
Jun 05
2024
|
Gabriel Leung |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+4.65%
|
-
|
|
Jun 05
2024
|
Timothy J Scannell |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+33.68%
|
-
|
|
Jun 05
2024
|
W Anthony Vernon |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+2.33%
|
-
|
|
Jun 05
2024
|
Kristin Stafford |
BUY
Grant, award, or other acquisition
|
Direct |
4,053
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 660K shares |
|---|---|
| Exercise of conversion of derivative security | 124K shares |
| Open market or private sale | 15.4K shares |
|---|